Navigation Links
Mayo clinic study finds gene bringing together animal and human research in alcoholism

ROCHESTER, Minn. -- An important genetic study conducted through Mayo Clinic has identified vital new information concerning alcoholism in subjects with European ancestry, according to a recent issue of Alcohol: Clinical and Experimental Research.

Research findings indicate that alcohol dependence is highly inheritable, although specific genes and their variations associated with this illness remain unknown. Animal model studies allow identification of potential candidate genes but their relevance to alcoholism in humans and its complications, including alcohol withdrawal and seizures, require additional research. Under the direction of Victor Karpyak, M.D., Ph.D., of the Mayo Clinic Department of Psychiatry and Psychology, a team of clinical and basic scientists investigated the sequence of the human MPDZ gene and its association with risks for alcohol dependence and alcohol withdrawal seizures.

"We have long known that the presence of severe withdrawal and seizures indicates strong physical dependence on alcohol," states Dr. Karpyak. "Focus on this group of subjects increases our chances to successfully identify the genetic variations associated with alcoholism in general and the presence of withdrawal symptoms specifically."

Sophisticated genetic research in mice isolated small regions on mouse chromosomes linked to severity of acute alcohol and barbiturate withdrawal measured by the presence and severity of seizures. Further research demonstrated that MPDZ gene is the only one in this chromosome region which has variants associated with severity of acute alcohol and barbiturate withdrawal and seizures.

The MPDZ protein is an important scaffolding brain protein, responsible for synaptic structure and plasticity. It is also known to be involved in learning and memory as well as seizures and epilepsy and, thus, is a good candidate for the human study focused on genetic predictors for alcohol withdrawal. Unfortunately, little was known about sequence variability of the MPDZ gene in humans. It is also a very long gene and its sequencing required considerable effort and costs.

To investigate the relevance of the model findings in animals for human alcoholism, Dr. Karpyak and his collaborators resequenced the human MPDZ gene in 61 subjects with a history of alcohol withdrawal seizures, 59 subjects with a history of withdrawal without seizures and 64 samples from non-alcoholic subjects -- all with European American ancestry. Sixty-seven new, mostly rare variants were discovered in the human MPDZ gene. Sequencing allowed the first opportunity of comparing the MPDZ gene in humans and mice. The new Mayo study found that the human gene does not have variations identical to those comprising the MPDZ gene associated with alcohol withdrawal seizures in mice.

Second, researchers used common variants to compare haplotype structure of the MPDZ gene in alcohol dependent subjects with and without history of withdrawal seizures and in controls who did not have alcoholism. The study revealed a significant association between MPDZ gene variant alcohol-dependency without seizures, compared to the control subjects. Contrary to initial hypothesis and animal findings, the study showed no significant association between MPDZ sequence variants and withdrawal seizures in humans. This suggests the potential role of MPDZ in alcoholism and/or related phenotypes other than alcohol withdrawal seizures.

This important new information supports further investigation of the role of MPDZ gene in alcoholism and its complications including withdrawal syndrome. It also indicates the importance of close collaboration between clinical and basic scientists that could provide critical insights into the mechanism of the association and reveal significant genetic markers of alcoholism.


Contact: John Murphy
Mayo Clinic

Related medicine news :

1. Mayo Clinic Study Finds Gene Bringing Together Animal and Human Research in Alcoholism
2. Sickle cell treatment developed at LA BioMed approved for phase 3 clinical trial
3. Wound Management Technologies, Inc. Announces the Presentation of Evidence Based Clinical Studies at the Symposium on Advanced Wound Care Conference in Dallas
4. Only 10 Seconds to Care by Dr. Wendy S. Harpham helps heal clinician-patient bonds
5. InfoLogix Selected by Gwinnett Medical Center to Transform Clinical Care Through Next-Generation Mobile Communications Solution
6. FDA Gives Clinical Trial Green Light on Drug to Treat Alzheimers Disease
7. TOPICA Begins Phase 2 Clinical Trial of Potent Antifungal, Luliconazole, in Athletes Foot
8. NKTR-105 Demonstrates Superior Antitumor Activity and Improved Pharmacokinetics Over Docetaxel in Preclinical Studies Presented at AACR
9. The Chicago School of Professional Psychology Announces Nations First Psy.D. Program in Clinical Forensic Psychology
10. The Anderson Clinic Chooses Medstrat PACS
11. Bio-Optronics Incorporates RxPaying(TM) Patient Stipend Debit Card Feature in Clinical Conductor(TM) Clinical Trial Management System (CTMS)
Post Your Comments:
(Date:6/27/2016)... ... June 27, 2016 , ... ... only authorized OSHA Training Institute Education Center headquartered in Northern California, has issued ... from extreme heat at their worksites. Employers with workers exposed to high ...
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their ... Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. , ... Pro X users can now reveal the media of their split screens with ...
(Date:6/27/2016)... , ... June 27, 2016 , ... ... mental health professionals, announced today its affiliation with Tennessee Counseling Association. ... to the network of the Tennessee Counseling Association, adding exclusive benefits and promotional ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... today announced its strategic partnership with Connance, a healthcare industry leader providing ... companies’ proven, proprietary technology combine to provide health systems, hospitals and ambulatory ...
(Date:6/27/2016)... NY (PRWEB) , ... June 27, 2016 , ... ... using cutting edge technology to revolutionize the emergency ambulance transport experience for the ... are aware of how Uber has disrupted the taxi industry through the use ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... SYDNEY , June 26, 2016 One of ... , has announced the formation of a new biotechnology company, Noxopharm ... raise $6m in an IPO and to list on the ASX. ... drug candidate, NOX66, ready to enter a Phase 1 clinical study ... been designed to address one of the biggest problems facing cancer ...
(Date:6/26/2016)... -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) ... Improvements Act of 1976, as amended ("HSR"), with respect ... Nasdaq: CPXX ) expired effective June 24, ... As previously announced on May 31, 2016, Jazz Pharmaceuticals ... which Jazz Pharmaceuticals has commenced a tender offer for ...
(Date:6/26/2016)... -- VMS Rehab Systems, Inc. ( ) reported today ... to build a strong and stable market for trading ... the OTC Markets-pink current trading platform. Explains ... seeing an anomaly in market trading activities that may ... Company, but shareholders and market players as well. I ...
Breaking Medicine Technology: